Nevertheless, the monitoring of serum NF-L levels has shown to be useful for evaluating the response of patients with SOD1-ALS to treatment with the antisense oligonucleotide tofersen [88]. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.